Like n com_老虎社区_美港股上老虎

miaomee
2021-12-24

Like n comment pls

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?

Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":698339602,"tweetId":"698339602","gmtCreate":1640302478946,"gmtModify":1640302480586,"author":{"id":3569375896365334,"idStr":"3569375896365334","authorId":3569375896365334,"authorIdStr":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":36,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like n comment pls</body></html>","htmlText":"<html><head></head><body>Like n comment pls</body></html>","text":"Like n comment pls","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698339602","repostId":1172289344,"repostType":4,"repost":{"id":"1172289344","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"Pfizer, Inc.&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;Paxlovid,&nbsp;has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;Merck &amp; Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action:&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-12-24 07:26\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\nPfizer, Inc.&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;Paxlovid,&nbsp;has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;Merck &amp; Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action:&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":749,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":15,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?

评论（2）

热议股票